Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Memphis | OTHER |
Not provided
Not provided
Not provided
Not provided
The aim of the clinical trial is to evaluate the efficacy of two novel hydration products on rehydration following exercise.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TP1 | Experimental | Participants will be administered TP1 during one of the experimental visits. |
|
| TP2 | Experimental | Participants will be administered TP2 during one of the experimental visits. |
|
| Placebo | Placebo Comparator | Participants will be administered placebo during one of the experimental visits. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TP1 | Other | Participants will be administered TP1 during one of the experimental visits. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Relative rehydration | To determine the effect of the test products (TPs) on relative rehydration after exercise, as compared to placebo via percent plasma volume change and plasma osmolality | Through study completion, an average of 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Hydration status via sweat loss | To determine the effect of the TPs on hydration status, as compared to placebo via sweat loss | Through study completion, an average of 8 weeks |
| Participants reported outcomes |
| Measure | Description | Time Frame |
|---|---|---|
| Relative effects of dehydration and rehydration | To explore the relative effects of dehydration and rehydration from the TPs and control on cognitive function, as compared to placebo via NIH cognitive toolbox - Flanker inhibitory control and attention testing performance | Through study completion, an average of 8 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michael Lelko, MS | Contact | 6787934226 | michael.lelko@liquid-iv.com |
| Name | Affiliation | Role |
|---|---|---|
| Richard Bloomer, PhD | University of Memphis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Memphis | Recruiting | Memphis | Tennessee | 38152 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003681 | Dehydration |
| ID | Term |
|---|---|
| D014883 | Water-Electrolyte Imbalance |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| TP2 |
| Other |
Participants will be administered TP2 during one of the experimental visits. |
|
| Placebo | Other | Participants will be administered placebo during one of the experimental visits. |
|
To determine the effect of the TPs on participant reported outcomes, as compared to placebo via bloating, exertion, exhaustion, thermal sensation, feeling of refreshment, stomach upset, and thirst
| Through study completion, an average of 8 weeks |
| Exercise performance |
To explore the effect of the TPs on exercise performance, as compared to placebo via time to exhaustion |
| Through study completion, an average of 8 weeks |
| D013568 | Pathological Conditions, Signs and Symptoms |